Evaluating Alkermes (ALKS) Valuation After Recent Share Price Momentum

Context for Alkermes stock

Alkermes (ALKS) has been on investors’ radar after recent share price moves, with the stock showing gains over the past week, month, and past 3 months that stand out against its longer term return profile.

With the company valued at about US$5.9b and reporting revenue of US$1.6b and net income of US$152.7m, many investors are now focusing on whether the current valuation still reflects its fundamentals.

See our latest analysis for Alkermes.

At the current share price of US$35.40, Alkermes has recently posted a 7-day share price return of 5.0% and a year to date share price return of 25.3%. The 1-year total shareholder return of 16.5% and 5-year total shareholder return of 61.8% suggest momentum has been building over a longer horizon.

If Alkermes’s recent move has you reassessing your watchlist, this can be a good moment to look at other biopharma opportunities using a healthcare focused screener such as 35 healthcare AI stocks

With Alkermes trading at US$35.40, some investors see a discount to analyst targets and intrinsic estimates, while others point to recent strong returns and profit growth. This raises the question of whether there is meaningful upside remaining or whether the market is already pricing in future growth.

Most Popular Narrative: 20% Undervalued

With Alkermes last closing at $35.40 against a narrative fair value of $44.24, the most followed storyline frames the stock as trading at a clear discount, built on a detailed view of its sleep franchise, orexin program, and long term cash flow potential.

The company is benefitting from margin expansion efforts and cost discipline, seen in lower cost of goods sold post divestiture of lower margin manufacturing operations. Together with growing proprietary product sales, this is driving higher net margins and increasing free cash flow generation.

Read the complete narrative.

Curious what underpins that valuation gap. The narrative leans on specific revenue growth paths, shifting profit margins, and a premium future earnings multiple. The exact mix matters.

Result: Fair Value of $44.24 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on assumptions that could shift, including rising R&D spend around orexin trials and Alkermes’s reliance on a relatively concentrated product portfolio.

Find out about the key risks to this Alkermes narrative.

Another View: Multiples Paint a Tougher Picture

While the narrative fair value of $44.24 points to upside, the P/E ratio tells a more cautious story. Alkermes trades on 38.6x earnings, well above the US Biotechs industry at 17.8x, the peer average at 20.4x, and a fair ratio of 25.8x that the market could move toward. For you, that gap highlights valuation risk if sentiment cools, so which signal do you give more weight to?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With the story divided between upside potential and valuation risk, this is a good time to check the data yourself and move quickly. Start by weighing the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Alkermes is already on your radar, do not stop there. Broaden your opportunity set now so you are not relying on a single story.

• Target potential mispricings by scanning 51 high quality undervalued stocks that pair stronger fundamentals with prices some investors may be overlooking.
• Prioritise resilience by checking 71 resilient stocks with low risk scores built around companies with steadier risk profiles that can help balance bolder positions.
• Hunt for future standouts early by reviewing the screener containing 23 high quality undiscovered gems before the wider market pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com